TCON TRACON Pharmaceuticals Inc.

1.03
-0.08  -7%
Previous Close 1.11
Open 1.09
Price To Book 1.07
Market Cap 30767467
Shares 29,871,327
Volume 266,750
Short Ratio
Av. Daily Volume 127,687

SEC filingsSee all SEC filings

  1. 8-K - Current report 181217570
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167359
  3. 8-K - Current report 181166279
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181058802
  5. 8-K - Current report 181058785

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due December 2018.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 2 data due 2020.
TRC253
Prostate cancer
Phase 2 AVANTE trial initiation announced July 25, 2017. Data due mid-2019.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with poster presented January 19, 2018 at ASCO GI showing 2/8 partial responses. Full data to be presented at GI ASCO January 17-19, 2019.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 top-line data due December 2018.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 primary endpoint not met - November 19, 2018.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2019.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis due 1Q 2019.
TRC105 (TAPPAS)
Angiosarcoma cancer

Latest News

  1. TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  2. TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
  3. TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
  4. TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting
  5. TRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma
  6. Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study
  7. Factors of Influence in 2018, Key Indicators and Opportunity within Sun Hydraulics, FIS, TRACON Pharmaceuticals, Kona Grill, Endava PLC Sponsored ADR, and Chembio Diagnostics — New Research Emphasizes Economic Growth
  8. Edited Transcript of TCON earnings conference call or presentation 7-Nov-18 9:30pm GMT
  9. Tracon: 3Q Earnings Snapshot
  10. TRACON Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  11. The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie
  12. TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018
  13. Shareholders Should Check The Ownership Structure Of TRACON Pharmaceuticals Inc (NASDAQ:TCON)
  14. Edited Transcript of TCON earnings conference call or presentation 8-Aug-18 8:30pm GMT
  15. TRACON Pharmaceuticals, Inc. to Host Earnings Call

SEC Filings

  1. 8-K - Current report 181217570
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167359
  3. 8-K - Current report 181166279
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181058802
  5. 8-K - Current report 181058785
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002314
  7. 8-K - Current report 181001410
  8. 8-K - Current report 18947072
  9. 8-K - Current report 18902787
  10. 8-K - Current report 18896943